Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 06 Oct, 15:42 UTC

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

science

Sources

• T2Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trialBioPharma Dive / Healthcare Dive / MedTech Dive06 Oct, 15:42